International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 515-523

  Dawood, S ^a   Merajver, S D ^b   Viens, P ^c   Vermeulen, P B ^d   Swain, S M ^e   Buchholz, T A ^f   Dirix, L Y ^d   Levine, P H ^g   Lucci, A ^f   Krishnamurthy, S ^f   Robertson, F M ^f   Woodward, W A ^f   Yang, W T ^f   Ueno, N T ^f   Cristofanilli, M ^h  

^a DUBAI HOSPITAL   (United Arab Emirates)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c INSTITUT PAOLI CALMETTES   (France)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

^e WASHINGTON CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

^h FOX CHASE CANCER CENTER   (United States)

Author keywords

Guidelines; Inflammatory breast cancer; Management

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE; LAPATINIB; LYMPHATIC VESSEL ENDOTHELIAL RECEPTOR 1; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN PROX 1; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC GUANINE NUCLEOTIDE BINDING PROTEIN; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DISTANT METASTASIS; DRUG SAFETY; ECHOGRAPHY; EVENT FREE SURVIVAL; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; INFLAMMATORY BREAST CANCER; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PUNCH BIOPSY; REVIEW; STANDARDIZATION; SURVIVAL TIME; TUMOR BIOPSY;

EID: 78650608807     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq345     Document Type: Review

References (62)

1. Lee B, Tannenbaum E. Inflammatory carcinoma of the breast. Surg Gynecol Obstet 1924; 39: 580-595.
2. Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology and End Results (SEER) Program. J Natl Cancer Inst 1985; 74: 291-297.
3. Haagensen CD. Inflammatory carcinoma. In Diseases of the Breast. Philadelphia, PA: W.B. Saunders 1956.
4. Breast. In Green F, Page D, Fleming I et al. (eds), AJCC Cancer Staging Manual, 6th edition. New York: Springer-Verlag 2002; 225-281.
5. Kim T, Lau J, Erban J. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin Breast Cancer 2006; 7: 386-395.
6. Bonnier P, Charpin C, Lejeune C et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer 1995; 62: 382-385.
7. Jardines L, Haffty B, Theriault R. Locally advanced, locally recurrent and metastatic breast cancer. In Pazdur R, Coia L, Hoskins W, Wagman L (eds), Cancer Management A Multidisciplinary Approach, 3rd edition. Melville, NY: PRR 1999; 73-88.
8. Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast. A pathologic definition. Cancer 1974; 33: 1045-1047.
9. Neely JC. The role of simple skin biopsy in uncertain inflammatory carcinoma of the breast. Am Surg 1958; 24: 836-838.
10. Charpin C, Bonnier P, Khouzami A et al. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res 1992; 12: 591-597.
11. Harvey HA, Lipton A, Lawrence BV et al. Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol 1982; 21: 42-44.
12. Nguyen DM, Sam K, Tsimelzon A et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 2006; 12: 5047-5054.
13. Zell JA, Tsang WY, Taylor TH et al. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 2009; 11: R9.
14. Hance KW, Anderson WF, Devesa SS et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005; 97: 966-975.
15. Parton M, Dowsett M, Ashley S et al. High incidence of HER-2 positivity in inflammatory breast cancer. Breast 2004; 13: 97-103.
16. Dawood S, Broglio K, Gong Y et al. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 2008; 112: 1905-1911.
17. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. San Antonio Breast Cancer Symposium. San Antonio, TX, 2008.
18. Gonzalez-Angulo AM, Sneige N, Buzdar AU et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res 2004; 10: 6215-6221.
19. Riou G, Le MG, Travagli JP et al. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 1993; 85: 1765-1767.
20. Cabioglu N, Gong Y, Islam R et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol 2007; 18: 1021-1029.
21. Gong Y, Gonzalez-Angulo A, Broglio K et al. Expression of Notch-1 and Bcatenin: defining the molecular portrait of inflammatory breast cancer. Breast Cancer Res Treat 2006; 100: S299.
22. Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH. A novel human xenograft model of inflammatory breast cancer. Cancer Res 1999; 59: 5079-5084.
23. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 2001; 61: 5231-5241.
24. Van der Auwera I, Van Laere SJ, Van den Eynden GG et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004; 10: 7965-7971.
25. van Golen KL, Wu ZF, Qiao XT et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60: 5832-5838.
26. van Golen KL, Davies S, Wu ZF et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999; 5: 2511-2519.
27. Kleer CG, Griffith KA, Sabel MS et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 2005; 93: 101-110.
28. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999; 81: 682-687.
29. Gunhan-Bilgen I, Ustun EE, Memis A. Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology 2002; 223: 829-838.
30. Chow CK. Imaging in inflammatory breast carcinoma. Breast Dis 2005; 22: 45-54.
31. Yang WT, Le-Petross HT, Macapinlac H et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008; 109: 417-426.
32. Shenkier T, Weir L, Levine M et al. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ 2004; 170: 983-994.
33. Danforth DN Jr, Aloj L, Carrasquillo JA et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002; 75: 135-146.
34. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005; 35: 84-99.
35. van der Hoeven JJ, Krak NC, Hoekstra OS et al. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004; 22: 1253-1259.
36. Bellon JR, Livingston RB, Eubank WB et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004; 27: 407-410.
37. Tran A, Pio BS, Khatibi B et al. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. J Nucl Med 2005; 46: 1455-1459.
38. Carkaci S, Macapinlac HA, Cristofanilli M et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009; 50: 231-238.
39. Ueno NT, Buzdar AU, Singletary SE et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997; 40: 321-329.
40. Harris EE, Schultz D, Bertsch H et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2003; 55: 1200-1208.
41. Baldini E, Gardin G, Evagelista G et al. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer 2004; 5: 358-363.
42. Low JA, Berman AW, Steinberg SM et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004; 22: 4067-4074.
43. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin Breast Cancer 2004; 4: 415-419.
44. Veyret C, Levy C, Chollet P et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer 2006; 107: 2535-2544.
45. Cheng YC, Rondon G, Yang Y et al. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant 2004; 10: 794-804.
46. Conti F, Carpano S, Sergi D et al. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: longterm results]. Clin Ter 2007; 158: 331-341.
47. Viens P, Palangie T, Janvier M et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 1999; 81: 449-456.
48. Hurley J, Doliny P, Reis I et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24: 1831-1838.
49. Van Pelt AE, Mohsin S, Elledge RM et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 2003; 4: 348-353.
50. Limentani SA, Brufsky AM, Erban JK et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007; 25: 1232-1238.
51. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21: 46-53.
52. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375(9712): 377-384.
53. Cristofanilli M, Boussen H, Baselga J et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat 2006; 100: S14.
54. Kaufmann M, von Minckwitz G, Bear HD et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18: 1927-1934.
55. Hortobagyi G, Singletary S, Strom E (eds): Treatment of Locally Advanced and Inflammatory Breast Cancer. Philadelphia, PA: Lippincott, Williams & Wilkins 2000.
56. Vlastos G, Fornage BD, Mirza NQ et al. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg 2000; 179: 446-452.
57. Stearns V, Ewing CA, Slack R et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002; 9: 235-242.
58. Chin PL, Andersen JS, Somlo G et al. Esthetic reconstruction after mastectomy for inflammatory breast cancer: is it worthwhile? J Am Coll Surg 2000; 190: 304-309.
59. Slavin SA, Love SM, Goldwyn RM. Recurrent breast cancer following immediate reconstruction with myocutaneous flaps. Plast Reconstr Surg 1994; 93: 1191-1204; discussion 205-207.
60. Motwani SB, Strom EA, Schechter NR et al. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 76-82.
61. Bristol IJ, Woodward WA, Strom EA et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2008; 72: 474-484.
62. Khatcheressian JL, Wolff AC, Smith TJ et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24: 5091-5097.